AbbVie Reports Strong Q4, Stock Rises Amid Positive Outlook

AbbVie surpasses Q4 expectations with strong revenue and EPS. The promising outlook could enhance investor confidence going forward.

Date: 04-02-2025

AI Rating: 7

Quarterly Performance Highlights

AbbVie (NYSE: ABBV) reported its fourth-quarter results, showcasing revenues and earnings that exceeded analysts' expectations. The company generated $15.1 billion in sales and earned $2.16 per share, surpassing consensus estimates of $14.8 billion and $2.11 respectively.

This performance indicates a solid demand for its drug offerings, specifically Rinvoq and Skyrizi, despite facing challenges like declining Humira sales, which dropped 49% to $1.7 billion. On a positive note, Skyrizi and Rinvoq saw impressive year-on-year sales growth of 58% and 46%, respectively, which highlights the company's ability to pivot from challenges associated with Humira's biosimilar competition.

AbbVie reported a year-on-year revenue growth of 5.6%, demonstrating resilience and adaptability in a competitive market. Moreover, the outlook for the upcoming years remains promising, with earnings projected to be $12.22 for 2025, slightly exceeding the $12.18 consensus estimate. The company's long-term guidance includes high single-digit compound annual revenue growth through 2029, particularly bolstered by rising expectations for Skyrizi and Rinvoq, which are set to contribute an additional $4 billion in revenue by 2027.

Key Metrics Assessment

The rise of ABBV stock by 5% following the results showcases a market response to AbbVie’s strong performance. Nevertheless, it’s essential to consider AbbVie's historical returns, which indicated inconsistency with a 0% return in 2023 and a marginally better 19% in 2024. The stock had notable returns of 32% and 24% in 2021 and 2022, respectively, but also faced external factors such as increased competition and previous clinical trial failures that could hinder future performance.

In conclusion, AbbVie appears poised for growth, with its stock currently trading at a P/S ratio of 5.8x, just above its three-year average of 5.0x. Investors' sentiments may lean positively moving forward, provided the company continues to navigate challenges effectively and leverages its growth sources in Skyrizi and Rinvoq.

Stocks: ABBV